ARTICLE | Clinical News
EBI-005: Phase Ib/IIa data
July 1, 2013 7:00 AM UTC
Top-line data from a double-blind, placebo-controlled, U.S. Phase Ib/IIa trial in 74 patients showed that thrice-daily topical EBI-005 for 6 weeks significantly improved signs and symptoms of dry eye ...